Sugi Predict

Sugi Predict / Compounds / SCHEMBL940218

SCHEMBL940218

SCHEMBL940218

CC(C)(C)OC(=O)N1CCNC(c2ccccc2)C1

nearest known ligand 0.50

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.50
▸ RORC P51449 4/20 0.48
▸ GPR119 Q8TDV5 2/20 0.48
▸ USP30 Q70CQ3 4/20 0.46
▸ JAK2 O60674 1/20 0.44
▸ JAK1 P23458 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ HPGDS O60760 2/20 0.43
▸ TACR1 P25103 1/20 0.42
▸ ROCK2 O75116 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19745334 1.00 MAPK1 (0.50) MAPK1RORCGPR119USP30JAK2
SCHEMBL28225677 1.00 MAPK1 (0.50) MAPK1RORCGPR119USP30JAK2
SCHEMBL5651780 1.00 MAPK1 (0.50) MAPK1RORCGPR119USP30JAK2
Hydrochloric Acid SCHEMBL28503227 0.99 MAPK1 (0.49) MAPK1RORCGPR119USP30JAK2
SCHEMBL26102356 0.88 GPR119 (0.49) MAPK1RORCGPR119
SCHEMBL16026535 0.88 ESR2 (0.44) MAPK1RORCGPR119USP30KDM4E
SCHEMBL6017253 0.88 GPR119 (0.49) MAPK1RORCGPR119
SCHEMBL6028557 0.88 GPR119 (0.56) MAPK1GPR119KDM4EPKMHPGDS
SCHEMBL38661093 0.87 MAPK1 (0.45) MAPK1GPR119USP30
SCHEMBL3694373 0.87 RORC (0.44) MAPK1RORCGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282749-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-09-11 — — US disclosed
US-20250221998-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2025-07-10 — — US disclosed
EP-4504730-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 Dana-Farber Cancer Institute, Inc. (US) 2025-02-12 — — EP disclosed
CN-119365454-A Discovery of covalent EGFR inhibitors through cysteine 775 丹娜-法伯癌症研究院 2025-01-24 — — CN disclosed
EP-4469445-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
CN-118957627-A Chlor-alkali industrial anode tertiary amine molecular catalyst and preparation method thereof 清华大学 2024-11-15 — — CN disclosed
US-20240174634-A1 Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-05-30 — — US disclosed
EP-3475275-B1 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-04-10 — — EP disclosed
CN-117157285-A Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors 阿尔麦克探索有限公司 2023-12-01 — — CN disclosed
EP-4259620-A1 ALDEHYDE DEHYDROGENASE INHIBITORS AND THEIR THERAPEUTIC USE Cancer Research Technology Limited (GB) 2023-10-18 — — EP disclosed
WO-2009112845-A1 AMIDO-THIOPHENE COMPOUNDS AND THEIR USE THE UNIVERSITY OF EDINBURGH (GB) 2009-09-17 — — WO disclosed
WO-2009112845-A1 AMIDO-THIOPHENE COMPOUNDS AND THEIR USE THE UNIVERSITY OF EDINBURGH (GB) 2009-09-17 — — WO disclosed
US-20080076924-A1 Piperazines as P2X7 antagonists ABBOTT LABORATORIES 2008-03-27 — — US disclosed
US-7323464-B2 Pyridine and pyrimidine derivatives CELLTECH R&D LIMITED (GB) 2008-01-29 — — US disclosed
WO-2008005368-A2 PIPERAZINES AS P2X7 ANTAGONISTS ABBOTT LABORATORIES (US) 2008-01-10 — — WO disclosed
US-20070265258-A1 Quinazoline derivatives as phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 — — US disclosed
US-20050080258-A1 Pyridine and pyrimidine derivatives GENTEX CORPORATION 2005-04-14 — — US disclosed
EP-1448555-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES Celltech R & D Limited (GB) 2004-08-25 — — EP disclosed
WO-2003045941-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES CELLTECH R & D LIMITED (GB) 2003-06-05 — — WO disclosed
WO-2003022214-A2 PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282749-A1 COMPOUNDS AND METHODS OF USE CYP1B1, CYP2C19, UGT1A1 MAPK1 3879/4885RORC 641/4885GPR119 1520/4885
US-20080076924-A1 Piperazines as P2X7 antagonists P2RX7, P2RX1, P2RX2 MAPK1 862/4885RORC 763/4885GPR119 93/4885
US-20240174634-A1 Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use ALDH2, ALDH1A1, ALDH3A1 MAPK1 3250/4885RORC 528/4885GPR119 404/4885
US-20070265258-A1 Quinazoline derivatives as phosphodiesterase 10 inhibitors PDE12, PDE5A, PDE7A MAPK1 2232/4885RORC 2792/4885GPR119 96/4885
US-20050080258-A1 Pyridine and pyrimidine derivatives ROR1, MAPK1, IRAK1 MAPK1 2/4885RORC 12/4885GPR119 1339/4885
US-20250221998-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 EGFR, ERBB2, ERBB3 MAPK1 247/4885RORC 2510/4885GPR119 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.